Aclaris Therapeutics(ACRS) ZACKS·2024-11-06 14:05Core Viewpoint - Aclaris Therapeutics reported a quarterly loss of 0.08, marking a 37.50% earnings surprise [1]. Financial Performance - The company posted revenues of 9.28 million in the same quarter last year [2]. - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2]. Stock Performance - Aclaris shares have increased by approximately 111.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 21.2% [3]. Future Outlook - The company's earnings outlook will be crucial for determining the stock's immediate price movement, with current consensus EPS estimates at -0.65 for the current fiscal year [4][7]. - The estimate revisions trend for Aclaris is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]. Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8].